Supplementary Data Tables 1 from Immunogenomic Landscape of Neuroendocrine Prostate Cancer

Supplementary Data Tables 1 from Immunogenomic Landscape of Neuroendocrine Prostate Cancer

<p>Suppl Table S1. Clinical characteristics of metastatic patient cohortSuppl Table S2. The 361 gene signature identified in this study to classify T-cell immune clustersSuppl Table S3. The 80 immune and stroma related gene signatures used to quantify the TMESuppl Table S4. DEGs for SCLC versu...

Saved in:

書目詳細資料
主要作者:	Bhavneet Bhinder (14963342) (author)
其他作者:	Alison Ferguson (16424081) (author), Michael Sigouros (15045498) (author), Manik Uppal (14963345) (author), Ahmed G. Elsaeed (16424084) (author), Rohan Bareja (16424087) (author), Hussein Alnajar (16424090) (author), Kenneth Wha Eng (15382259) (author), Vincenza Conteduca (15045492) (author), Andrea Sboner (14963351) (author), Juan Miguel Mosquera (16424093) (author), Olivier Elemento (14956746) (author), Himisha Beltran (15284954) (author)
出版:	2025
主題:	Cancer Tumor Biology Clinical Research and Trials Genitourinary Cancers Prostate cancer Precision Medicine Tumor Microenvironment Immune cells and the microenvironment
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
由: Zachary Quinn (15052893)
出版: (2025)

Supplementary Table S2 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
由: Holly Tovey (16824233)
出版: (2025)

Supplementary Table S3 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
由: Holly Tovey (16824233)
出版: (2025)

Supplementary Tables S1-S4 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
由: Axel Stenmark Tullberg (15029928)
出版: (2025)

Figure 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
由: Robert L. Hollis (15034814)
出版: (2025)

Figure 2 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
由: Robert L. Hollis (15034814)
出版: (2025)

Figure 3 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
由: Robert L. Hollis (15034814)
出版: (2025)

Figure 4 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
由: Robert L. Hollis (15034814)
出版: (2025)

Figure 5 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
由: Robert L. Hollis (15034814)
出版: (2025)

Table 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
由: Robert L. Hollis (15034814)
出版: (2025)

Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
由: Alexander N. Shoushtari (15023909)
出版: (2025)

Suppl Data 2 from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer
由: Marija Pizurica (17060224)
出版: (2025)

Suppl. Data 1 from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer
由: Marija Pizurica (17060224)
出版: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
由: James S. Wilmott (15008931)
出版: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
由: James S. Wilmott (15008931)
出版: (2025)

Figure 1 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
由: Natalie C. Fisher (15046025)
出版: (2025)

Figure 2 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
由: Natalie C. Fisher (15046025)
出版: (2025)

Figure 3 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
由: Natalie C. Fisher (15046025)
出版: (2025)

Figure 4 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
由: Natalie C. Fisher (15046025)
出版: (2025)

Figure 5 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
由: Natalie C. Fisher (15046025)
出版: (2025)

Figure 6 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
由: Natalie C. Fisher (15046025)
出版: (2025)

Figure 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
由: Clare Vesely (505402)
出版: (2025)

Figure 2 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
由: Clare Vesely (505402)
出版: (2025)

Figure 3 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
由: Clare Vesely (505402)
出版: (2025)

Figure 4 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
由: Clare Vesely (505402)
出版: (2025)

Figure 5 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
由: Clare Vesely (505402)
出版: (2025)

Table 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
由: Clare Vesely (505402)
出版: (2025)

Supplementary Data from DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations
由: John Gallon (15096459)
出版: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
由: Ulka N. Vaishampayan (15051039)
出版: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
由: Ulka N. Vaishampayan (15051039)
出版: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
由: Ulka N. Vaishampayan (15051039)
出版: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
由: Ulka N. Vaishampayan (15051039)
出版: (2025)

Supplementary Data 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
由: Arian Lundberg (14960817)
出版: (2025)

Supplementary Data 2. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
由: Arian Lundberg (14960817)
出版: (2025)

Supplementary Figures 1 from Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors
由: Luana Guimaraes Sousa (16534377)
出版: (2025)

Table S2 from Hydrogen Sulfide Creates a Favorable Immune Microenvironment for Colon Cancer
由: Taohua Yue (14963045)
出版: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
由: Kankan Cao (16437263)
出版: (2025)

Table S2 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression
由: Junfeng Xu (16437141)
出版: (2025)

Table S3 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression
由: Junfeng Xu (16437141)
出版: (2025)

Supplementary Table 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
由: Arian Lundberg (14960817)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_60imgpih5ufgfgtdt1ihb9jaif